EVOQ Bio
Raising nowOperatingEVOQ Biomed, Inc.
Biotech · Salt Lake City, UT
EVOQ Bio is a pre-clinical drug development company engineering EVQ-218, a novel antimicrobial candidate targeting pathogens associated with multidrug-resistant lung infections. Peer-reviewed research published in the journal ACS Omega characterizes the precise nanoscale architecture of the platform, while a peer-reviewed study published in the journal Antibiotics demonstrates broad-spectrum antimicrobial activity and no observed resistance over 30 serial passages under conditions where standard-of-care antibiotics showed diminished performance. Supported by $498,000 in awards from the Cystic Fibrosis Foundation, the company has engaged with the FDA through a Pre-IND meeting and is advancing the program toward clinical trials.
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Cap table
Principal holders% as the filing states it, Jun 2, 2026
- EVOQ Nano, Inc.49,500,000 Class A Voting Common Stock99.0%of Class A Voting
Sold to the crowd
- Reg CF · Jun 2026Crowdfunding Stock $181K· 56 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
11 people
David Parkinson. David Parkinson is a public health subject matter expert focused on cystic fibrosis, informed by decades of advocacy and research engagement. A practicing attorney since 1998, he brings extensive legal experience in regulatory strategy, corporate governance, and healthcare innovation, supporting the development and commercialization of novel therapies addressing critical unmet medical needs.
Shaun Rothwell. CEO of EVOQ Bio, is a successful entrepreneur and business leader with a strong track record of building and scaling companies. He is now dedicating his experience and strategic vision to advancing EVQ-218 through pre-IND development and into human clinical trials, helping drive the company’s next phase of growth.
William Niedermeyer. Co-Founder of EVOQ Bio, is an inventor and nanotechnology pioneer with a background in applied physics. He developed patented nanoparticle fabrication methods enabling high-performance materials. His work underpins potentially breakthrough antimicrobial solutions targeting multi-drug resistant infections across therapeutic and device applications.
David Nilson. Leads development of the inhaled EVQ-218 therapeutic for pulmonary bacterial infections at EVOQ Bio, focusing on cystic fibrosis patients facing antibiotic-resistant bacteria. With 20+ years in biotech, pharmaceutical and genomics leadership, he spearheads scaling, partnerships, and preclinical-to-clinical advancement of this innovative metamaterial.
Board-certified oral and maxillofacial surgeon, cosmetic surgeon, and entrepreneur with extensive expertise in facial surgery, dental implantology, and aesthetic procedures. Founder and President of Oragen and co-founder of Rain Dental Implants, Dr. Jensen brings dual clinical and leadership experience to advancing innovative healthcare solutions. He provides strategic guidance on clinical development, regulatory pathways, and commercialization efforts for advanced medical platforms.
Ali Sharif, PhD. Experienced researcher in microbiology, molecular biology, neurobiology, genetics, and translational medicine. Published in leading journals and recipient of competitive NIH and foundation grants. Proven leader in assay development, now focused on advancing therapeutic development, including novel antimicrobial strategies targeting infectious diseases to improve clinical outcomes and address critical unmet medical needs.
Burke Nyal Perrett. Entrepreneur and business strategist with experience in venture development, capital formation, and scaling emerging technologies, has worked across multiple industries supporting early-stage growth and market positioning. He contributes strategic and financial guidance to EVOQ, supporting the advancement and commercialization of the EVQ-218 platform, including its potential application as an inhaled therapeutic for antibiotic-resistant pulmonary infections.
Peter Hutt. Former Chief Counsel of the FDA (1971–1975) and widely regarded by many as the “Father of Modern Food and Drug Law,” practiced FDA law for over five decades at Covington & Burling. He provides strategic regulatory guidance supporting the potentially breakthrough inhaled EVQ-218 therapeutic developed by EVOQ Bio for antibiotic-resistant pulmonary infections.
DeLyle Wade Bloomquist. Veteran executive and operator with decades of leadership across advanced manufacturing and technology-driven industries, has held senior roles guiding companies through scale, operational transformation, and strategic growth. He provides executive leadership and operational insight supporting the development and commercialization of the EVOQ platform technology, including its potential application as an inhaled therapeutic for antibiotic-resistant pulmonary infections.
Show 2 more peopleShow fewer
Paul Peters. Former U.S. Army Brigadier General and senior Department of Defense leader with deep experience in procurement, logistics, and large-scale operational leadership. He provides strategic and operational guidance to EVOQ, supporting the advancement and commercialization of the EVQ-218 platform, including its potential application across many varied industries.
Timothy Paul Stratford. International trade attorney and policy expert with extensive experience advising on cross-border regulatory frameworks and government relations, including prior service in senior roles at the Office of the U.S. Trade Representative. He provides strategic guidance to EVOQ on global regulatory positioning and market access, supporting the advancement and commercialization of the EVQ-218 platform, including its potential application for antibiotic-resistant pulmonary infections.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.